Sanofi SA (SASY.PA)
20 Oct 2016
BRUSSELS, Oct 18 German pharmaceuticals company Boehringer Ingelheim has offered concessions in an attempt to secure EU antitrust approval for its acquisition of Sanofi's animal health unit as part of a $20 billion asset swap.
* Science 37 secures $31m series b funding to expand clinical trial access to anyone, anywhere, anytime
Big pharmaceutical companies are waging courtroom patent battles against each other over biosimilars, as the line blurs between companies known for their innovative medicines and those that produce cheaper biotech knock-offs.
* Sanofi appoints Alan Main to executive committee and executive vice president, consumer healthcare Source text for Eikon: Further company coverage: (Reporting By Dominique Vidalon)
(The following statement was released by the rating agency) MILAN/LONDON, September 27 (Fitch) Fitch Ratings has affirmed L'Oreal SA's (L'Oreal) Short-Term Issuer Default Rating (IDR) and commercial paper (CP) programme at 'F1+'. The agency has also affirmed L'Oreal USA Inc's CP programme, guaranteed by L'Oreal, at 'F1+'. The ratings continue to reflect the company's strong market position and product portfolio as well as its robust geographical diversification. Also, L'Oreal continues to d
Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.
* The United States Biomedical Advanced Research and Development Authority (BARDA) agrees to fund the manufacture of an inactivated Zika vaccine for phase II development by Sanofi and its vaccines global business unit Sanofi Pasteur
French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
Sept 26 French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
* Sanofi and Regeneron announce dupilumab biologics license application accepted for priority review by U.S. FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)